Mozart Ther­a­peu­tics makes its of­fi­cial de­but, jump­ing in­to the hot Treg R&D field with some big-name in­vestors back­ing it

Treg cells have been get­ting more and more at­ten­tion re­cent­ly among au­toim­mune spe­cial­ists. There’s been Jeff Blue­stone’s Sono­ma, the $157 mil­lion launch of Gen­tiBio this sum­mer and Egle Ther­a­peu­tics — which launched just last week — to name a few.

Now, there’s a new Treg play­er jump­ing in that wants to dis­tin­guish it­self in the mar­ket: Mozart Ther­a­peu­tics. To­day, the biotech is emerg­ing from stealth in its of­fi­cial de­but with a $55 mil­lion Se­ries A — with a bunch of A-list Big Phar­ma names on board a syn­di­cate co-led by ARCH and Sofinno­va Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER